BLAINJECTIONSOLUTIONPriority Review
Approved
Aug 2023
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
23
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELREXFIO (elranatamab-bcmm) is a bispecific antibody (BSAB) approved by FDA in August 2023 as an injectable solution. It is a next-generation immunotherapy designed to engage T cells and tumor cells simultaneously, representing a novel mechanism in oncology. The drug is currently in growth phase and addresses unmet needs in hematologic malignancies.
Growth
Early-stage growth product with moderate competitive pressure (30%) suggests expanding commercial teams and rising revenue trajectory typical of post-approval ramp.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (23)
RE-RITE: Real-world Evaluation of Response, Implementation and Toxicity of Elranatamab
Started Nov 2026
400 enrolled
Myeloma Multiple
A Phase IV Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma That is Not Responding to Four or More Standard Treatments or Has Come Back After Several Standard Treatments
Started Oct 2026
75 enrolled
Relapsed/Refractory Multiple MyelomaMultiple Myeloma
HEME-25 Open-Label Feasibility Study of Elranatamab Utilized as Consolidation in Newly Diagnosed Plasmablastic Lymphoma With or Without HIV
Started Oct 2026
17 enrolled
Plasmablastic LymphomaHIVConsolidation
A Study of Elranatamab Outpatient Administration in Patients With Relapsed/Refractory Multiple Myeloma
Started Sep 2026
46 enrolled
Multiple Myeloma (MM)Multiple Myeloma RefractoryMultiple Myeloma in Relapse+1 more
A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"
Started Mar 2026
34 enrolled
Phase 2Radiotherapy-Induced Immune PrimingElranatamab+4 more
Worked on ELREXFIO at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.